Tracer library / [18F]FAPI-42
Structure of FAPI-42 (unlabelled parent compound, from PubChem)
Unlabelled parent compoundPubChem CID 139400498

[18F]FAPI-42

Also written as [18F]FAPI-42; [F-18]FAPI-42
Radionuclide
F-18 t½ 109.77 min
Modality
PET
Production route
—
Stage
—
Syntheses indexed
0
Fibrosis (non-oncologic)Autoimmune / immune-mediated systemic disease

What it is

Compound class
NOTA-FAPI-04 (fibroblast activation protein inhibitor, NOTA-conjugated small molecule)
Target / mechanism
Fibroblast activation protein (FAP) inhibitor targeting FAP-expressing cells PMID 41781161
Clinical application
PET/CT imaging for detection and activity scoring of IgG4-related disease PMID 41781161
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. Clinical Evaluation of [18F]AlF-NOTA-GL01 PET/CT in patients with solid tumors: a prospective comparison with [18F]FDG and an exploratory [18F]FAPI-42 subset.
    2026 · Eur J Nucl Med Mol Imaging · Prospective
  2. Differential [18F]FAPI-42 and [18F]FDG uptake patterns distinguish desmoid tumours from GISTs on PET/CT imaging.
    2026 · Eur J Nucl Med Mol Imaging · Retrospective
  3. Insights into lung cancer diagnosis and clinical management using [18F]F-fibroblast activation protein inhibitor (FAPI)-42 positron emission tomography/computed tomography (PET/CT).
    2025 · Ann Nucl Med · Retrospective
  4. Structure-Guided Designed [18F]-labeled FAPI for Enhanced Hydrophilicity: From Preclinical to First-In-Human Study.
    2026 · J Med Chem · Clinical study
  5. Development and Pilot Clinical Study of a Novel FAP-Targeted PET Tracer for PET Imaging of Tumors.
    2026 · Anal Chem · Clinical study
  6. Comparison of 18F-FAPI-42 PET for Detecting Cardiac Fibroblast Activation in Dilated Cardiomyopathy With Histopathology and CMR.
    2025 · JACC Cardiovasc Imaging · Clinical study
  7. Semiquantitative analysis of 18F-aluminum fluoride fibroblast activation protein inhibitor 42 PET/computed tomography in primary liver cancer and factors influencing imaging positivity rates.
    2025 · Nucl Med Commun · Clinical study
  8. First clinical investigation to predict lymphovascular and/or perineural invasion in gastric cancer using 18F-FAPI-42 PET/CT parameters.
    2025 · Eur J Nucl Med Mol Imaging · Clinical study
  9. Early 10-Minute Postinjection [18F]F-FAPI-42 uEXPLORER Total-Body PET/CT Scanning Protocol for Staging Lung Cancer Using HYPER Iterative Reconstruction.
    2025 · J Nucl Med Technol · Clinical study
  10. Design, Synthesis, and Evaluation of a Novel Positron Emission Tomography Tracer Targeting Fibroblast Activation Protein: From Bench to Bedside.
    2025 · J Med Chem · Clinical study
Show all 12 clinical studies
  1. Modification of Asp-Peptide Adapters: Giving the FAP-Targeted Radioligand a "Squirrel Tail".
    2025 · J Med Chem · Clinical study
  2. Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients.
    2024 · Eur J Nucl Med Mol Imaging · Clinical study

Need this precursor?We can point you to suppliers for [18F]FAPI-42, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph
not verified No Ph. Eur. check is recorded for this entry.
USP monograph
not verified No USP check is recorded for this entry.
AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activity
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); receptor ligand with a saturable target -> molar activity (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [18F]FAPI-42.

Get in touch

Notes

Added from reverse module search (stage 6); 4 article(s) with F-18. Compound class inferred from precursor name (not stated outright) -- PMID 41781161: 'the FAPI-04 precursor, 1,4,7-triazacyclononane-N, N', N"-triacetic acid (NOTA) FAPI-04, was obtained from Beijing PET Technology (Beijing, China).'. | Stage 28: added indication(s) inf-autoimmune from consolidated missing-rubric review.
Ask a question